NARS1

Across TCGA pan-cancer cohorts, NARS1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NARS1 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher NARS1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NARS1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and SKCM are the cancer types where NARS1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.225	0.752	<.001	33	view →
UCEC	DFS	Median	All	1.000	0.625	.007	28	view →
SKCM	DFS	Median	III,IV	0.058	0.648	.001	9	view →
LUAD	OS	Median	III,IV	0.228	0.677	.015	6	view →
LUSC	OS	Median	All	0.237	0.676	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NARS1–HNSC (OS)

Open the HNSC breakdown →